Overview

A Study To Evaluate the Safety, Tolerance, Pharmacokinetics/Pharmacodynamics and Efficacy of SYHA1402 Tablets For the Treatment of Patients With Diabetic Peripheral Neuropathy in China

Status:
Not yet recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the safety, tolerance, pharmacokinetics/pharmacodynamics and efficacy of SYHA1402 tablets for the treatment of patients with diabetic peripheral neuropathy (DPN) in China.
Phase:
Phase 2
Details
Lead Sponsor:
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.